Journal Browser

► Journal Browser

Immunotherapy in Gynecological Oncology: Current Strategies and New Innovative Approaches

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 6597

Share This Special Issue

Special Issue Editors

Special Issue Information

Immunotherapy (IT) is established as a standard treatment option for several malignancies, with the most important IT option being the immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 or CTLA-4 axis.

Across all entities of gynecological tumors, response rates to ICI monotherapy are rather moderate, except for the case of MSI^high tumors. Notable advances in molecular immunology have led to the development of combination therapy strategies targeting both tumor-intrinsic targets and the tumor microenvironment. Adoptive T cell transfer and vaccinations, most likely in combination with immunomodulation, may be a promising option and are the subject of current research.

This Special Issue aims to publish research articles, reviews and perspectives concentrating on translational and clinical aspects of immunotherapeutic approaches in gynecological tumors.

Besides highlighting the current development of immunotherapeutic strategies in clinical trials, papers dealing with tumor–immune system interaction, the identification of new immunotherapeutic targets or biomarkers or the (pre)clinical development of innovative immunotherapeutic (combination) approaches are particularly welcome.

PD Dr. Antonia Busse
Prof. Dr. Anne Letsch
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

endometrial cancer
ovarian cancer
cervix cancer
HPV-associated cancer
checkpoint molecules
immunomodulation
immunotherapeutic combinations
vaccines
cell therapy
biomarkers
tumor antigens

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

15 pages, 2583 KiB

Open AccessArticle

PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model

by Jiefu Jin, Ishwarya Sivakumar, Yelena Mironchik, Balaji Krishnamachary, Flonné Wildes, James D. Barnett, Chien-Fu Hung, Sridhar Nimmagadda, Hisataka Kobayashi, Zaver M. Bhujwalla and Marie-France Penet

Cancers 2022, 14(3), 619; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14030619 - 26 Jan 2022

Cited by 4 | Viewed by 3377

Abstract

(1) Background: Despite advances in surgical approaches and drug development, ovarian cancer is still a leading cause of death from gynecological malignancies. Patients diagnosed with late-stage disease are treated with aggressive surgical resection and chemotherapy, but recurrence with resistant disease is often observed following treatment. There is a critical need for effective therapy for late-stage ovarian cancer. Photoimmunotherapy (PIT), using an antibody conjugated to a near infrared (NIR) dye, constitutes an effective theranostic strategy to detect and selectively eliminate targeted cell populations. (2) Methods: Here, we are targeting program death ligand 1 (PD-L1) using NIR-PIT in a syngeneic mouse model of ovarian cancer. PD-L1 PIT-mediated cytotoxicity was quantified in RAW264.7 macrophages and ID8-Defb29-VEGF cells in culture, and in vivo with orthotopic ID8-Defb29-VEGF tumors. (3) Results: Treatment efficacy was observed both in vitro and in vivo. (4) Conclusions: Our data highlight the need for further investigations to assess the potential of using NIR-PIT for ovarian cancer therapy to improve the treatment outcome of ovarian cancer. Full article

(This article belongs to the Special Issue Immunotherapy in Gynecological Oncology: Current Strategies and New Innovative Approaches)

► Show Figures

Figure 1

Review

Jump to: Research

17 pages, 1007 KiB

Open AccessReview

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points

by Janina Świderska, Mateusz Kozłowski, Sebastian Kwiatkowski and Aneta Cymbaluk-Płoska

Cancers 2021, 13(23), 6063; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13236063 - 01 Dec 2021

Cited by 8 | Viewed by 2643

Abstract

Ovarian cancer is one of the most fatal cancers in women worldwide. Cytoreductive surgery combined with platinum-based chemotherapy has been the current first-line treatment standard. Nevertheless, ovarian cancer appears to have a high recurrence rate and mortality. Immunological processes play a significant role in tumorigenesis. The production of ligands for checkpoint receptors can be a very effective, and undesirable, immunosuppressive mechanism for cancers. The CTLA-4 protein, as well as the PD-1 receptor and its PD-L1 ligand, are among the better-known components of the control points. The aim of this paper was to review current research on immunotherapy in the treatment of ovarian cancer. The authors specifically considered immune checkpoints molecules such as PD-1/PDL-1 as targets for immunotherapy. We found that immune checkpoint-inhibitor therapy does not have an improved prognosis in ovarian cancer; although early trials showed that a combination of anti-PD-1/PD-L1 therapy with targeted therapy might have the potential to improve responses and outcomes in selected patients. However, we must wait for the final results of the trials. It seems important to identify a group of patients who could benefit significantly from treatment with immune checkpoints inhibitors. However, despite numerous trials, ICIs have not become part of routine clinical practice for the treatment of ovarian cancer. Full article

(This article belongs to the Special Issue Immunotherapy in Gynecological Oncology: Current Strategies and New Innovative Approaches)

► Show Figures